Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706469 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants
A Phase 1 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03706469 is a Phase 1 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 16 participants.
The verdict
NCT03706469, a Phase 1 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the oral BA of TAK-831 T3 tablet formulation relative to TAK-831 T2 tablet formulation under fasting conditions and to assess the effect of food on the pharmacokinetics (PK) of TAK-831 T3 tablet formulation.
Interventions
- DRUG TAK-831 T2
- DRUG TAK-831 T3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-10-18 |
| Est. Completion | 2018-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03706469
The ClinicalTrials.gov registry entry for NCT03706469 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-831 T2 is the first listed.
NCT03706469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03706469 about?
NCT03706469 is a clinical study titled "A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants". The purpose of this study is to assess the oral BA of TAK-831 T3 tablet formulation relative to TAK-831 T2 tablet formulation under fasting conditions and to assess the effect of food on the pharmacokinetics (PK) of TAK-831 T3 tablet formulation.
What is the current status of trial NCT03706469?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-10-18. Estimated completion is 2018-12-22.
What interventions are being tested in trial NCT03706469?
The interventions under investigation include: TAK-831 T2 (DRUG), TAK-831 T3 (DRUG).
Who is sponsoring clinical trial NCT03706469?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.